MetaCap

Baxter International (BAX) vs Insulet (PODD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Baxter International (BAX) has outperformed Insulet (PODD) over the past year, gaining 38.7% versus a loss of 59.8%. Over five years, PODD leads with a -54.9% price change compared with -66.7% for BAX. Baxter International is the larger company by market cap ($13.14 billion vs $9.24 billion), about 1.4 times the size, while Insulet is growing revenue faster (+30.7% vs +5.7%).

On valuation, Baxter International trades at a lower forward P/E (12.4x vs 16.8x for Insulet). Baxter International pays a dividend yielding 0.16%, while Insulet does not currently pay one. Insulet converts more of its revenue into profit, with a net margin of 9.1% versus -8.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BAX+38.67%PODD-59.79%
+61%-3%-66%
Nov 21, 20251 yearNov 20, 2026
BAX-67.97%PODD-55.76%
+21%-32%-85%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BAX versus PODD key metrics
MetricBAXPODD
Share price$25.39$133.17
Market cap$13.14B$9.24B
1-day change0.00%-2.96%
YTD return+32.86%-53.15%
1-year return+38.67%-59.79%
5-year return-66.72%-54.92%
P/E ratio (TTM)—21.76
Forward P/E12.4116.83
EPS (TTM)$-1.21$6.12
Dividend yield0.16%0.00%
Annual dividend$0.04$0.00
Revenue (latest FY)$11.24B$2.71B
Revenue growth (YoY)+5.72%+30.73%
Net income (latest FY)$-957.00M$247.10M
Gross margin30.05%71.63%
Operating margin-2.74%17.50%
Net margin-8.51%9.12%
52-week high$30.00$342.13
52-week low$15.73$126.40
Distance from 52-week high-15.37%-61.08%
Analyst consensusholdbuy
Avg. price target upside+7.33%+33.60%
Average volume6.38M1.61M
Shares outstanding517.35M69.37M
Employees37,5005,400
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BAX has outperformed PODD by 98.5 percentage points over the past year.
  • Insulet is more profitable, keeping 9.1 cents of every revenue dollar as net income versus -8.5 cents for Baxter International.
  • Insulet grew revenue faster in its latest fiscal year (+30.73% vs +5.72%).

About Baxter International

BAX stock →

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.

Health Care · Medical/Dental Instruments · 37,500 employees

About Insulet

PODD stock →

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.

Health Care · Medical/Dental Instruments · 5,400 employees

BAX vs PODD FAQ

Which is bigger, Baxter International or Insulet?

Baxter International (BAX) is larger, with a market capitalization of $13.14B compared with $9.24B for Insulet (PODD).

Which stock has performed better over the past year, BAX or PODD?

BAX returned +38.67% over the past 12 months, compared with -59.79% for PODD (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Baxter International or Insulet?

Baxter International pays a dividend yielding 0.16%, while Insulet does not currently pay a regular dividend.

Are Baxter International and Insulet in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons